T1	Participants 294 354	multicenter, double-blind, randomized, parallel-group study.
T2	Participants 433 474	cisplatin chemotherapy (> or = 60 mg/m2).
T3	Participants 632 816	40% and 49% of patients in Cycles 2 and 3, respectively, for the 10 micrograms/kg group, and in 42% and 38% of patients in Cycles 2 and 3, respectively, for the 40 micrograms/kg group.
T4	Participants 1043 1082	high-dose cisplatin-based chemotherapy.
